This little-known genome editing stock is poised to surge more than 60%, JPMorgan says
JPMorgan thinks investors should flock to biotechnology company Beam Therapeutics , which the firm says stands to benefit from increased market share and a strong gene therapy pipeline.…
Read more This little-known genome editing stock is poised to surge more than 60%, JPMorgan says